IPP Bureau
Illuminova ’26 showcases AI-driven future of medical education at SRM
By IPP Bureau - April 29, 2026
SRM Medical College Hospital and Research Centre hosts undergraduate research expo highlighting innovation, interdisciplinary collaboration, and the role of artificial intelligence
Exciva initiates Phase 2/3 SERENADA trial for Alzheimer’s agitation therapy
By IPP Bureau - April 29, 2026
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
AbbVie seeks FDA nod for RINVOQ use in severe alopecia areata
By IPP Bureau - April 29, 2026
After Phase 3 results show major hair regrowth gains
FDA okays AstraZeneca’s triple therapy Breztri for asthma
By IPP Bureau - April 29, 2026
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Cubo set to transform decentralised diagnostics with Compact RT-PCR innovation
By IPP Bureau - April 29, 2026
Avio Smart Market Stack Limited and Huwel Lifesciences unveil portable, cost-efficient molecular testing platform
NADMED Limited appoints James Lee as CEO to drive global expansion
By IPP Bureau - April 29, 2026
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Laguna Diagnostics secures FDA breakthrough tag for mRNA test in psychiatric diagnosis
By IPP Bureau - April 29, 2026
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
Granules India Q4FY26 revenue jumps 23% to Rs 14,706 million; FY26 revenue at Rs 53,656 million
By IPP Bureau - April 29, 2026
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
Apollo launches its 76th hospital, boosts tech-led healthcare in India
By IPP Bureau - April 28, 2026
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers
By IPP Bureau - April 28, 2026
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Concept Medical unveils promising 3-year data for sirolimus balloon therapy
By IPP Bureau - April 28, 2026
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
Rheumatology Awareness Walkathon 2026 spotlights arthritis and autoimmune care
By IPP Bureau - April 28, 2026
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
Biosimilars gain momentum as US market sees 92 approvals: Samsung Bioepis report
By IPP Bureau - April 28, 2026
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
.png "EssilorLuxottica receives FDA authorization for its Essilor Stellest lens for myopia control")
EssilorLuxottica receives FDA authorization for its Essilor Stellest lens for myopia control
By IPP Bureau - April 28, 2026
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
OMRON Healthcare to donate 3,000 blood pressure monitors globally for hypertension screening
By IPP Bureau - April 28, 2026
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
